Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001140361-25-019266
Filing Date
2025-05-15
Accepted
2025-05-15 16:02:09
Documents
81
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ef20047563_10q.htm   iXBRL 10-Q 1415607
2 EXHIBIT 31.1 ef20047563_ex31-1.htm EX-31.1 12546
3 EXHIBIT 31.2 ef20047563_ex31-2.htm EX-31.2 12347
4 EXHIBIT 32.1 ef20047563_ex32-1.htm EX-32.1 5749
  Complete submission text file 0001140361-25-019266.txt   7907063

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ird-20250331.xsd EX-101.SCH 80243
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ird-20250331_cal.xml EX-101.CAL 34832
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ird-20250331_def.xml EX-101.DEF 412730
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE ird-20250331_lab.xml EX-101.LAB 852842
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ird-20250331_pre.xml EX-101.PRE 560466
84 EXTRACTED XBRL INSTANCE DOCUMENT ef20047563_10q_htm.xml XML 1096845
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709 248-681-9815
Opus Genetics, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34079 | Film No.: 25952441
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)